Findings

What do systematic reviews say?

13 questions · 13 findings · 8 reviews · Gynaecological, Neuro-oncology and Orphan Cancer

Sort:Best matchNewest Highest certainty Download CSV

No studies found 6 · 46.2%GRADE not reported 0 · 0%Very low 3 · 23.1%Low 2 · 15.4%Moderate 2 · 15.4%High 0 · 0%

Dexrazoxane vs no cardioprotective intervention or placebo

Quality of life · adults with cancer receiving anthracyclines

The review found no eligible studies for this question.

1 finding from 1 review

Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Green tea extract supplementation vs placebo

Quality of life · adults (aged at least 18 years)

The review found no eligible studies for this question.

1 finding from 1 review

Green tea (Camellia sinensis) for the prevention of cancer 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Probiotics vs placebo

Quality of life · participants with cancer treated with radiotherapy (with or without chemotherapy)

1 finding from 1 review

Probiotics for the prevention or treatment of chemotherapy‐ or radiotherapy‐related diarrhoea in people with cancer 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 72 participants
Low

Summary of findings: bevacizumab vs placebo

Quality of life · people previously treated with radiosurgery or fractionated radiotherapy to the brain or head and neck region with a diagnosis of brain…

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the treatment of brain radionecrosis after radiotherapy or radiosurgery 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings table ‐ Newly‐diagnosed EOC: PARPi monotherapy vs placebo (maintenance therapy)

QoL · newly‐diagnosed EOC

1 finding from 1 review

Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 362 participants
Moderate

Bethanechol vs placebo

QoL

The review found no eligible studies for this question.

1 finding from 1 review

Postoperative interventions for preventing bladder dysfunction after radical hysterectomy in women with early‐stage… 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Laigle‐Donadey 2019: dexamfetamine sulfate vs placebo

Health‐related quality of life European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ‐C30). Scale from: 0 to 100 (a higher score means a better outcome) · people with a primary brain tumour

1 finding from 1 review

Interventions for the management of fatigue in adults with a primary brain tumour 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 41 participants
Very low

Probiotics vs placebo

Quality of life ‐ not measured · participants with cancer treated with chemotherapy

The review found no eligible studies for this question.

1 finding from 1 review

Probiotics for the prevention or treatment of chemotherapy‐ or radiotherapy‐related diarrhoea in people with cancer 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Probiotics vs placebo

Quality of life ‐ not measured · participants with cancer treated with radiotherapy (with or without chemotherapy)

The review found no eligible studies for this question.

1 finding from 1 review

Probiotics for the prevention or treatment of chemotherapy‐ or radiotherapy‐related diarrhoea in people with cancer 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Laigle‐Donadey 2019: dexamfetamine sulfate vs placebo

Quality of life EORTC QLQ‐BN 20 · people with a primary brain tumour

1 finding from 1 review

Interventions for the management of fatigue in adults with a primary brain tumour 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 41 participants
Very low

Lifestyle interventions vs placebo or usual care

Quality of life: FACT‐G (12 months) · weight reduction in obesity to improve survival in women with endometrial cancer

1 finding from 1 review

Interventions for weight reduction in obesity to improve survival in women with endometrial cancer 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 89 participants
Very low

Porter 2020: armodafinil vs placebo

Quality of life, self‐rated at post‐treatment · people with a primary brain tumour

1 finding from 1 review

Interventions for the management of fatigue in adults with a primary brain tumour 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 232 participants
Low

Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi monotherapy vs placebo (maintenance therapy)

QoL · platinum‐sensitive recurrent EOC

1 finding from 1 review

Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 339 participants
Moderate